Substance Abuse

Showing 69 articles
Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Business

Apple vs. Meta: A Tale of Two Tech Titans in the Magnificent Seven

As earnings season unfolds, Apple and Meta Platforms both posted impressive results, but their paths diverge sharply. Apple's growth reaccelerates on iPhone strength, while Meta's robust outlook is shadowed by soaring AI investments. The debate over which stock offers the better value is heating up.

Business

Tilray Brands Bets Big on Beverages as Stock Languishes: A Valuation Deep Dive

Amidst a major brand refresh for Terrapin Beer and the announcement of SweetWater Brewing's 2026 festival lineup, Tilray Brands is aggressively pushing its beverage division into the mainstream. However, this consumer-facing drive contrasts sharply with a prolonged stock slump, raising critical questions about the company's true market value and future trajectory.

World

South Africa and Israel expel envoys in deepening feud

South Africa ordered Israel's top diplomat to leave the country within 72 hours on Friday, citing a "series of violations" and prompting the Israeli government to expel Pretoria's own diplomatic representative.The Israeli foreign ministry swiftly responded that South Africa's senior diplomatic representative, Shaun Byneveldt, "is persona non grata and must leave Israel within 72 hours".